 <h1>Gefitinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to gefitinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, gefitinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking gefitinib:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain or tenderness</li>
<li>clay colored stools</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>diarrhea, severe</li>
<li>fever</li>
<li>headache</li>
<li>itching or skin rash</li>
<li>loss of appetite</li>
<li>nausea and vomiting</li>
<li>swelling of the feet or lower legs</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Burning, dry, or itching eyes</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>difficult breathing</li>
<li>discharge or excessive tearing</li>
<li>dry eyes</li>
<li>general feeling of discomfort or illness</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>thickening of bronchial secretions</li>
<li>troubled breathing</li>
<li>troubled or quick, shallow breathing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloody, black, or tarry stools</li>
<li>eye redness, irritation, or pain</li>
<li>heartburn</li>
<li>indigestion</li>
<li>joint or muscle pain</li>
<li>red skin lesions, often with a purple center</li>
<li>severe abdominal or stomach pain, cramping, or burning</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>vomiting of material that looks like coffee grounds, severe and continuing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of gefitinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Redness or soreness around fingernails or loosening of the fingernails</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to gefitinib: oral tablet</i></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Interstitial lung disease or ILD-like adverse reactions<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (up to 40%), increased ALT (up to 38%)</p>
<p><b>Common</b> (1% to 10%): Increased bilirubin</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatitis/hepatic failure</p>
<p><b>Rare</b> (less than 0.1%): Fatal hepatotoxicity<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 29%), nausea (up to 18%), vomiting (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Stomatitis, dry mouth, pancreatitis, dehydration (secondary to diarrhea, nausea, vomiting, or anorexia)</p>
<p><b>Uncommon</b> (0.1% to 1%): GI perforation<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Keratitis, conjunctivitis, blepharitis, dry eye</p>
<p><b>Uncommon</b> (0.1% to 1%): Corneal erosion/aberrant eyelash growth<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Rare</b> (less than 0.1%): CNS hemorrhage</p>
<p><b>Frequency not reported</b>: Cerebrovascular events<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Skin reactions (up to 47%)</p>
<p><b>Common</b> (1% to 10%): Nail disorder, alopecia</p>
<p><b>Rare</b> (less than 0.1%): Bullous conditions (including toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme), cutaneous vasculitis<sup>[Ref]</sup></p><p>Reported skin reactions: acne/acne pustular, dermatitis (acneiform and exfoliative), drug eruption, dry skin, erythema, folliculitis, pruritus, rash (erythematous, exfoliative, generalized, macular, maculo-papular, papular, pruritic, pustular, vesicular), skin exfoliation, skin toxicity, and xeroderma.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Proteinuria (up to 35%)</p>
<p><b>Common</b> (1% to 10%): Elevated blood creatinine, cystitis</p>
<p><b>Rare</b> (less than 0.1%): Hemorrhagic cystitis</p>
<p><b>Frequency not reported</b>: Renal failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (up to 17%), anorexia (10%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (up to 17%)</p>
<p><b>Common</b> (1% to 10%): Pyrexia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Hemorrhage (including epistaxis and hematuria)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Allergic reactions (including angioedema and urticaria)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about gefitinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>8 Reviews</li>
<li>Drug class: EGFR inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gefitinib Oral &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Iressa</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to gefitinib: oral tablet</i></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Interstitial lung disease or ILD-like adverse reactions<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (up to 40%), increased ALT (up to 38%)</p><p><b>Common</b> (1% to 10%): Increased bilirubin</p><p><b>Uncommon</b> (0.1% to 1%): Hepatitis/hepatic failure</p><p><b>Rare</b> (less than 0.1%): Fatal hepatotoxicity<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 29%), nausea (up to 18%), vomiting (up to 14%)</p><p><b>Common</b> (1% to 10%): Stomatitis, dry mouth, pancreatitis, dehydration (secondary to diarrhea, nausea, vomiting, or anorexia)</p><p><b>Uncommon</b> (0.1% to 1%): GI perforation<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Keratitis, conjunctivitis, blepharitis, dry eye</p><p><b>Uncommon</b> (0.1% to 1%): Corneal erosion/aberrant eyelash growth<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Rare</b> (less than 0.1%): CNS hemorrhage</p><p><b>Frequency not reported</b>: Cerebrovascular events<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Skin reactions (up to 47%)</p><p><b>Common</b> (1% to 10%): Nail disorder, alopecia</p><p><b>Rare</b> (less than 0.1%): Bullous conditions (including toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme), cutaneous vasculitis<sup>[Ref]</sup></p><p>Reported skin reactions: acne/acne pustular, dermatitis (acneiform and exfoliative), drug eruption, dry skin, erythema, folliculitis, pruritus, rash (erythematous, exfoliative, generalized, macular, maculo-papular, papular, pruritic, pustular, vesicular), skin exfoliation, skin toxicity, and xeroderma.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Proteinuria (up to 35%)</p><p><b>Common</b> (1% to 10%): Elevated blood creatinine, cystitis</p><p><b>Rare</b> (less than 0.1%): Hemorrhagic cystitis</p><p><b>Frequency not reported</b>: Renal failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (up to 17%), anorexia (10%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Asthenia (up to 17%)</p><p><b>Common</b> (1% to 10%): Pyrexia<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Hemorrhage (including epistaxis and hematuria)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Allergic reactions (including angioedema and urticaria)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p><h2>More about gefitinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>8 Reviews</li>
<li>Drug class: EGFR inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Gefitinib Oral &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>